

## Short Review on Dapagliflozin

Vishnu Vardhan\*

Department of Biotechnology, Gokaraju Rangaraju Institute of Engineering and Technology, Bachupally, Kukatpally, Hyderabad, Telangana, India

### Review Article

Received: 20/02/2017  
Revised: 14/03/2017  
Accepted: 18/03/2017

#### \*For Correspondence

Vishnu Vardhan, Department of  
Biotechnology, Gokaraju  
Rangaraju Institute of  
Engineering and Technology,  
Bachupally, Kukatpally,  
Hyderabad, Telangana, India, Tel:  
+91 9888484451.

#### E-mail:

vishnupannala80@gmail.com

#### Keywords:

Dapagliflozin,  
Cotransporter, Hypoglycaemia

#### ABSTRACT

Dapagliflozin is a medication of the gliflozin class, used to treat type 2 diabetes. It was produced by Bristol-Myers Squibb in organization with AstraZeneca. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by diminishing the measure of sugar the body assimilates and expanding the measure of sugar that leaves the body. Dapagliflozin is utilized alongside diet and work out, and now and again with different drugs, to lower glucose levels in patients with type 2 diabetes (condition in which glucose is too high in light of the fact that the body does not create or utilize insulin ordinarily). Dapagliflozin is in a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It brings down glucose by creating the kidneys to dispose of more glucose. Dapagliflozin is not used to treat type 1 diabetes (condition in which the body does not deliver insulin and, in this manner, can't control the measure of sugar in the blood) or diabetic ketoacidosis (a genuine condition that may create if high glucose is not treated).

### INTRODUCTION

After some time, individuals who have diabetes and high glucose can create genuine or life-debilitating confusions, including coronary illness, stroke, kidney issues, nerve harm, and eye issues. Taking Dapagliflozin, rolling out way of life improvements (e.g., abstain from food, work out, stopping smoking), and consistently checking your glucose may deal with your diabetes and enhance your wellbeing. This treatment may likewise diminish your odds of showing at least a bit of kindness assault, stroke, or different diabetes-related complexities, for example, kidney disappointment, nerve harm (numb, chilly legs or feet; diminished sexual capacity in men and ladies), eye issues, including changes or loss of vision, or gum infection [1-9].

### STRUCTURE OF DAPAGLIFLOZIN

Dapagliflozin comes as a tablet to take by mouth. It is brought as a rule with or without sustenance once per day in the morning. Take Dapagliflozin at around a similar time each day. Take after the headings on your solution name painstakingly, and ask your specialist or drug specialist to clarify any part you don't get it. Take Dapagliflozin precisely as coordinated [10-18]. Try not to take pretty much of it or take it more regularly than recommended by your specialist.

Repressing renal glucose reabsorption through the sodium-glucose cotransporter (SGLT) offers an insulin-free contrasting option to controlling blood glucose focuses in patients with type 2 diabetes. While the larger part of glucose is reabsorbed from glomerular filtrate by SGLT2, which is overwhelmingly communicated in the kidney S1 portion of the proximal tubule, SGLT1 reabsorbs glucose in the distal S3 fragment of the renal proximal tubule and in addition from the small digestive system. Dapagliflozin is an original, particular SGLT inhibitor that squares glucose transport with around 100-overlay selectivity for SGLT2 ( $K_i = 6$  nM;  $EC_{50} = 1.1$  nM) over SGLT1 ( $K_i = 390$

nM). After single oral measurements extending from 0.1 to 1.0 mg/kg, Dapagliflozin increments urinary glucose discharge in both ordinary and diabetic rats, enhances glucose resistance in typical rats, and lessens hyperglycemia in Zucker diabetic greasy rats. Within two weeks of treating diabetic rats with 0.1 to 1.0 mg/kg Dapagliflozin, fasting and encouraged glucose levels have been appeared to be altogether brought down as a consequence of expanded glucose use joined by decreased glucose production [19-28].

Dapagliflozin 3-O-glucuronide is the essential metabolite of Dapagliflozin, with 61% of the Dapagliflozin dosage recouped in the pee as this metabolite. The digestion system of Dapagliflozin is principally intervened by UGT1A9-subordinate glucuronide conjugation. The significant metabolite, Dapagliflozin 3-O-glucuronide, is not a SGLT2 inhibitor.

Dapagliflozin comes as a tablet to take by mouth. It is brought ordinarily with or without sustenance once every day in the morning. Take Dapagliflozin at around a similar time each day. Take after the bearings on your medicine name painstakingly, and ask your specialist or drug specialist to clarify any part you don't get it. Take Dapagliflozin precisely as coordinated. Try not to take pretty much of it or take it more frequently than endorsed by your specialist [29-37].

## TOXICITY

Contrasted with fake treatment treated patients, patients with direct renal debilitation treated with Dapagliflozin did not have change in glycemic control and had more renal-related antagonistic responses and more bone cracks; accordingly, Dapagliflozin ought not to be started in this populace. In view of its component of activity, Dapagliflozin is not anticipated that would be viable in patients with serious renal impedance (eGFR under 30 mL/min/1.73 m<sup>2</sup>) or ESRD [38-49].

Dapagliflozin may cause serious side effects including:

Drying out (the loss of body water and salt), which may make you feel bleary eyed, swoon, woozy, or powerless, particularly when you stand up (orthostatic hypotension). You might be at a higher danger of lack of hydration in the event that you have low circulatory strain; take prescriptions to bring down your pulse, including water pills (diuretics); are 65 years old or more established; are on a low salt eating routine, or have kidney issues [50-61].

Ketoacidosis happened in individuals with type 1 and type 2 diabetes amid treatment with dapagliflozin. Ketoacidosis is a genuine condition which may require hospitalization and may prompt to death. Indications may incorporate queasiness, tiredness, spewing, inconvenience breathing, and stomach torment. In the event that you get any of these side effects, quit accepting dapagliflozin and summon your human services supplier right. In the event that conceivable, check for ketones in your pee or blood, regardless of the possibility that your glucose is under 250 mg/dL [62-67].

Kidney issues, sudden kidney harm happened in individuals taking dapagliflozin. Converse with your specialist immediately in the event that you decrease the sum you eat or drink, or on the off chance that you lose fluids; for instance, from regurgitating, the runs, or extreme warmth introduction [68-70].

Genuine urinary tract diseases (UTI), some that prompt to hospitalization, happened in individuals taking dapagliflozin. Tell your specialist on the off chance that you have any signs or indications of UTI including a smoldering feeling when passing pee, a need to urinate frequently, the need to urinate immediately, torment in the lower a portion of your stomach (pelvis), or blood in the pee with or without fever, back agony, sickness, or regurgitating [71-76].

Low glucose (hypoglycaemia) can happen in the event that you bring dapagliflozin with another drug that can bring about low glucose, for example, sulfonylureas or insulin. Side effects of low glucose incorporate shaking, sweating, quick pulse, tipsiness, appetite, cerebral pain, and peevishness. Take after your human services supplier's directions for treating low glucose [77-80].

Vaginal yeast contaminations in ladies who take dapagliflozin. Converse with your medicinal services supplier on the off chance that you encounter vaginal smell, white or yellowish vaginal (release might be uneven or look like curds), or vaginal tingling [81-87].

Yeast disease of skin around the penis (balanitis) in men who take dapagliflozin. Converse with your human services supplier on the off chance that you encounter redness, tingling, or swelling of the penis; rash of the penis; noxious release from the penis; or agony in the skin around penis. Certain uncircumcised men may have swelling of

the penis that makes it hard to pull back the skin around the tip of the penis [88-95]. Increment in awful cholesterol (LDL-C). Your social insurance supplier ought to check your LDL-C amid treatment with dapagliflozin.

Bladder tumor: In investigations of dapagliflozin in individuals with diabetes, bladder tumor happened in a couple of a bigger number of individuals who were taking dapagliflozin than in individuals who were taking different diabetes medicines [96-102]. There were excessively few instances of bladder tumor, making it impossible to know whether bladder disease was identified with dapagliflozin. Tell your human services supplier immediately on the off chance that you have blood or red shading in faecal matter or agony while you urinate.

## REFERENCES

1. Savu O, et al. Prospective Analysis of L-arginine Dependent Nitric Oxide Production in the Blood of Patients with Type 2 Diabetes 5 Years after First Clinical Onset. *J Diabetes Metab.* 2016;7:706.
2. Bailey CJ, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2010;375:2223-2233.
3. Tutelyan VA, et al. Innovative Approaches in the Development of Specialized Food Products of Optimized Composition for Patients with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:711.
4. Alam A, et al. Efficacy of Spirulina (Tahlab) in Patients of Type 2 Diabetes Mellitus (Ziabetes Shakri) - A Randomized Controlled Trial. *J Diabetes Metab.* 2016;7:710.
5. He Z. Diagnosis and Treatment of Diabetic Nephropathy in Type 1 and Type 2 Diabetes Patients. *J Mol Biomark Diagn.* 2016;7:295.
6. Petrovic D. Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus. *J Diabetic Complications Med.* 2016;1:e102.
7. Pleskovic A, et al. Polymorphisms rs1800587 and rs1143634 of the Interleukin-1a Gene are associated with the Progression of Carotid Atherosclerosis in Caucasians with Type 2 Diabetes Mellitus. *J Diabetic Complications Med.* 2016;1:113.
8. Asegaonkar SB. Vitamin D and Type 2 Diabetes Mellitus: Indian Perspectives. *J Diabetic Complications Med.* 2016;1:110.
9. Kupsal K, et al. Metformin Combinatorial Therapy for Type 2 Diabetes Mellitus. *J Metabolic Syndr.* 2016;5:210.
10. Tofighi A, et al. Blood Levels of Resistin, Glycemic Indices and Lipid Profile in Women with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:702.
11. Mehdizadeh A, et al. Investigation of Plasma Visfatin Changes in Women with Type 2 Diabetes followed by Endurance, Resistance and Combined Exercise: The Role of Lipid Profile, Glycemic Indices and Insulin Resistance. *J Diabetes Metab.* 2016;7:703.
12. Sun J, et al. PTP1B, A Potential Target of Type 2 Diabetes Mellitus. *Mol Biol.* 2016;5:174.
13. Saiedullah M. Insulin Sensitivity or Resistance in Type 2 Diabetes Mellitus with Obesity. *Diabetes Case Rep.* 2016;1:e102.
14. Chobanyan N, et al. Evaluation of Environmental Risk Factors for Type 2 Diabetes in Sint Maarten. *J Environ Anal Toxicol.* 2016;6:386.
15. Rachel C, et al. The -765G>C Cyclooxygenase-2 Promoter Polymorphism is associated with Type 2 Diabetes Mellitus, Low High-density Lipoprotein and Manifest Angina. *J Diabetes Metab.* 2016;7:686.
16. Bayramova AN. Gastroenterological Diseases as a Complications of Type 2 Diabetes Mellitus. *J Gastrointest Dig Syst.* 2016;6:442.
17. Tang X, et al. A Randomized Controlled Clinical Trial on the Treatment of Type 2 Diabetes with Depression by Wu Ling Capsule. *J Clin Trials.* 2016;6:273.
18. Hernandez HE, et al. Baseline Anemia Analysis of Hispanic Dialysis Patients with and without Type 2 Diabetes. *J Mol Histol Med Physiol.* 2016;1:105.
19. Shizuma T, et al. A Case of Back Abscess and Diabetic Ketoacidosis in a Patient with Type 2 Diabetes Mellitus. *Diabetes Case Rep.* 2016;1:106.
20. Szybinski Z. Primary Prevention of Obesity and Type 2 Diabetes Mellitus. *Epidemiology (Sunnyvale).* 2016;6:243.
21. Demchuk MP, et al. Efficacy of Fetal Stem Cells use in Complex Treatment of Patients with Insulin-resistant Type 2 Diabetes Mellitus. *J Stem Cell Res Ther.* 2016;6:342.
22. Cakir OO, et al. Visceral Fat Volume is a Better Predictor for Insulin Resistance than Abdominal Wall Fat Index in Patients with Prediabetes and Type 2 Diabetes Mellitus. *Intern Med.* 2016;6:220.
23. Berezin AE. Can Osteoprotegerin be a Target of Therapy in Type 2 Diabetes Mellitus? *Metabolomics.* 2016;6:172.

24. Heidari A. Molecular Dynamics and Monte–Carlo Simulations for Replacement Sugars in Insulin Resistance, Obesity, LDL Cholesterol, Triglycerides, Metabolic Syndrome, Type 2 Diabetes and Cardiovascular Disease: A Glycobiological Study. *J Glycobiol.* 2016;5:e111.
25. Demirsoy IH, et al. TCF7L2 rs7903146 Gene Variation Is Associated with Risk of Type 2 Diabetes in Turkish Population. *J Clin Med Genomics.* 2016;4:141.
26. Nayeri A, et al. Type 2 Diabetes Mellitus is an Independent Risk Factor for Postoperative Complications in Patients Surgically Treated for Meningioma. *J Neurol Neurophysiol.* 2016;7:368.
27. Merlo S, et al. Polymorphisms rs699 and rs4762 of the Angiotensinogen Gene and Progression of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus. *J Diabetic Complications Med.* 2016;1:107.
28. Kurioka S, et al. Combination Therapy of Pitavastatin and Sitagliptin Improves the Estimated Glomerular Filtration Rate in Patients with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:667.
29. Abdulrhman MA. Honey as a Sole Treatment of Type 2 Diabetes Mellitus. *Endocrinol Metab Syndr.* 2016;5:232.
30. Nørgaard SK, et al. Prepregnancy Body Mass Index and Offspring Birth Weight in Women with Type 1 and Type 2 Diabetes. *J Preg Child Health.* 2016;3:244.
31. Zain M, et al. Association of Family History of Type 2 Diabetes with COMT Gene Polymorphism (I/D) in Pakistani Population. *J Down Syndr Chr Abnorm.* 2016;2:108.
32. Sharma JN. The Role of Bradykinin System in Type 2 Diabetes. *J Diabetes Metab.* 2016;7:658.
33. Montiel-Tellez BSPA, et al. Ec.+62G>A and g.-420C>G RETN Polymorphisms and the Risk of Developing Type 2 Diabetes and Obesity: Original Research on a Mexican Population and Meta-analysis. *Endocrinol Metab Syndr.* 2016;5:228.
34. Cardoso C, et al. Cost-effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Portugal. *J Diabetes Metab.* 2016;7:653.
35. Bankura B, et al. Inter-patient Variability in Clinical Efficacy of Metformin in Type 2 Diabetes Mellitus Patients in West Bengal, India. *J Metabolic Syndr.* 2016;5:198.
36. Samson M, et al. Understanding the Importance of Gene and Environment in the Etiology and Prevention of Type 2 Diabetes Mellitus in High-Risk Populations. *Oral health case Rep.* 2016;1:112.
37. Tong CV, et al. Glycemic Variability among Older Adults with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:652.
38. Lukacs K, et al. Primary Hyperlipidemia, Acute Pancreatitis and ketoacidosis in an Adolescent with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:651.
39. Franek E, et al. Leader 8: Type 2 Diabetes Patients: A Comparison of Baseline Characteristics of Eastern and Western European Participants with Established Cardiovascular Disease in the LEADER Trial. *J Diabetes Metab.* 2016;7:646.
40. Mahmoud AA, et al. Association of Interleukin-10 (–592A/C) Gene Polymorphism with its Level in Type 2 Diabetes Mellitus with and without Nephropathy. *J Mol Genet Med.* 2016;10:199.
41. Constantin C and Ranetti A. Assessment of a Key Message in Newly Diagnosed Type 2 Diabetes Mellitus Patients Considering Their Educational Program. *J Nutr Disorders Ther.* 2016;6:182.
42. Grandy S, Shaunik A, Hardy E. Effects of Glucagon-Like Peptide-1 Receptor Agonists on  $\beta$ -Cell Function in Patients with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:643.
43. Berezin A. The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus. *Endocrinol Metab Syndr.* 2016;5:1000217.
44. Bosek I, et al. Evaluation of Interferon-Gamma in Patients with Type 2 Diabetes and Colorectal Cancer. *J Diabetes Metab.* 2016;7:639.
45. Roever L and Borges ASR. Mortality in Patients with Type 2 Diabetes: Impact of Age, Glycemic Control, and Renal Complications. *J Diabetes Metab.* 2015;7:e119.
46. Mussa BM, et al. Prevalence of Hypertension and Obesity among Emirati Patients with Type 2 Diabetes. *J Diabetes Metab.* 2016;7:638.
47. Mackawy AMH, et al. Association of Protein Tyrosine Phosphatase 1B (PTPN1) Gene Polymorphisms (1023C>A and 467T>C) With Type 2 Diabetes: A Case-Control Study. *J Clin Med Genomics.* 2016;3:135.
48. Wimalawansa SJ. Preventing Long-Term Complications of Obesity, Type 2 Diabetes, and Metabolic Syndrome: Common Sense Approach *Endocrinol Metab Syndr.* 2015;4:206.
49. Gniuli D and Capria F. Late Onset Bartter Syndrome in Type 2 Diabetes Mellitus Scarcely Compensated: A Case Report Study. *Endocrinol Metab Syndr.* 2015;4:201.
50. Vavruch C and Nystrom FH. Leptin in Patients with Type 2 Diabetes. *Primary Health Care.* 2015;5:209.
51. Saleem F, et al. Home Medication Review in Improving Patient Medication Adherence and Minimizing Medication Wastage among Type 2 Diabetes Patients. *Health Econ Outcome Res Open Access.* 2015;1:104.
52. Raj U, et al. In Silico Identification of Novel Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes Mellitus. *Enz Eng.* 2015;4:128.

53. Numaguchi R, et al. Leptin is Associated with Local Stiffness of the Carotid Artery in Overweight Patients with Type 2 Diabetes. *J Diabetes Metab.* 2015;6:627.
54. Zhang P, et al. Global healthcare expenditure on diabetes for 2010 and 2030. *Diabetes Res ClinPract.* 2010;87:293-301.
55. Barnett AH, et al. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. *Int J ClinPract.* 2010;64:1121-1129.
56. Aoki Y. Surprising Results of the EMPA-REG OUTCOME Study have brought a New Insight into Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Type 2 Diabetes. *Trop Med Surg.* 2015;3:199.
57. Levy V, et al. Potential Budgetary Impact of Large Scale Screening of Small Fiber Neuropathy in the Follow-Up of Patients with Type 2 Diabetes in France. *J Diabetes Metab.* 2015;6:618.
58. Min T, et al. Predicting the Resolution of Type 2 Diabetes after Bariatric Surgical Procedures: A Concise Review. *J Diabetes Metab.* 2015;6:617.
59. Krishnan D, et al. The Impact of Diet Counselling on Type 2 Diabetes Mellitus: An Indian Case Study. *J Diabetes Metab.* 2015;6:610.
60. Eguchi T, et al. The Efficacy of Pioglitazone Treatment in Myotonic Dystrophy Type 1 and Type 2 Diabetes Mellitus Patient. *J Clin Case Rep.* 2015;5:584.
61. Sieng S, et al. Achievement of Processes of Care for Patients with Type 2 Diabetes in General Medical Clinics and Specialist Diabetes Clinics in Thailand. *Epidemiology (sunnyvale).* 2015;S2:004.
62. Lilia CM, et al. Endothelial Dysfunction Evaluated using Photoplethysmography in Patients with Type 2 Diabetes. *J Cardiovasc Dis Diagn.* 2015;3:219.
63. Iwao T, et al. Liraglutide With or Without Metformin Ameliorates Liver Function and Fatty Liver in Obese Patients with Type 2 Diabetes Mellitus. *J Diabetes Metab.* 2015;6:598.
64. Abdelgadir EIE, et al. Liraglutide Effect on Blood Pressure, Lipids Profile, and Liver Enzymes in Arab Patients with Type 2 Diabetes Mellitus: A Prospective LIRA-BPL Study. *J Diabetes Metab.* 2015;6:591.
65. Unjiati, et al. Chromium and Zinc Level of Patients with Type 2 Diabetes and Non-Diabetes. *Biochem Physiol.* 2015;S5:010.
66. Zreik R, et al. The Overall Evolution of Lebanese Patients with Type 2 Diabetes Over 5 Years: A Comparison from the International Diabetes Management Practices Study Results. *Endocrinol Metab Syndr.* 2015;4:181.
67. Pirozzi FF and Dias MAF. Pulmonary Artery Relaxation was Best with Increasing GLP1 than the Metabolic Improvement in Patients with Type 2 Diabetes. *J Diabetes Metab.* 2015;S13:013.
68. Liu J, et al. Nicotinic Acetylcholine Receptors and Cardiac Vagal activity in Rats with Type 2 Diabetes. *J Diabetes Metab.* 2015;S13:012.
69. Nauck MA, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial. *Diabetes Care.* 34:2015-2022.
70. Goring S, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. *Diabetes ObesMetab.* 2010;16:433-442.
71. European Medicines Agency (2012) Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus.
72. Gershell L. Type 2 diabetes market. *Nat Rev Drug Discov.* 2015;4:367-368.
73. Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2012;35:1364-1379.
74. The Cochrane Collaboration (2011) Section 8.5: The Cochrane Handbook. The Cochrane Collaboration's tool for assessing risk of bias.
75. Dias S, et al. NICE DSU technical support document 2: a general linear modelling framework for pairwise and network meta-analysis of randomised controlled trials 2011.
76. Dakin HA, et al. Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. *Statistics in medicine.* 2011;30:2511-2535.
77. Stevens JW. A note on dealing with missing standard errors in meta-analyses of continuous outcome measures in WinBUGS. *Pharm Stat.* 2011;10: 374-378.
78. Dias S, et al. Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment. *Med Decis Making.* 2013;33:618-640.
79. LunnD, et al. The BUGS book: A practical introduction to Bayesian analysis 2012.
80. DeFronzo RA, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. *Diabet Med.* 2010;27:309-317.
81. Mavian AA, et al. Managing type 2 diabetes: balancing HbA1c and body weight. *Postgrad Med.* 2010;122: 106-117.

82. Harris R, et al. Metan: fixed-and random-effects meta-analysis. *Stata journal*. 2008;8:3.
83. Bucher HC, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. *Journal of clinical epidemiology*. 1997;50:683-691.
84. Pratley RE, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet*. 2010;375:1447-1456.
85. Derosa G, et al. Vildagliptin added to metformin on beta-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. *Diabetes Technology and Therapeutics*. 2010;14:475-484.
86. Monami M, et al. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2014;16:457-466.
87. Ahrén B, et al. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). *Diabetes Care*. 2013;36:2543-2550.
88. Bergenstal RM, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. *Lancet*. 2010;376:431-439.
89. Bergenstal RM, et al. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). *Diabetes Ther*. 2012;3:13.
90. Bolinder J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. *J Clin Endocrinol Metab*. 2012;97:1020-1031.
91. Bolli G, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab*. 2008;10:82-90.
92. Bosi E, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Care*. 2007;30:890-895.
93. Charbonnel B, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. *Diabetes Care* 29:2638-2643.
94. DeFronzo RA, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care*. 2005;28:1092-1100.
95. DeFronzo RA, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care*. 2009;32:1649-1655.
96. Kaku K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. *Curr Med Res Opin*. 2009;25:1111-1119.
97. Nauck M, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. *Diabetes Care*. 2009;32:84-90.
98. Pan C, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. *Diabetes Obes Metab*. 2012;14:737-744.
99. Raz I, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. *Curr Med Res Opin*. 2008;24:537-550.
100. Yang W, et al. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. *Diabetes Res Clin Pract*. 2011;94:217-224.
101. Yang W, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. *J Diabetes*. 2012;4:227-237.
102. Ferrannini E, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. *Diabetes Obes Metab*. 2009;11:157-166.